Talk:Erdheim–Chester disease

From WikiProjectMed
Jump to navigation Jump to search

Quote or paraphrase to avoid plagiarism

Since the text of the lead is almost identical to the cited reference at http://www.diseasesdatabase.com/umlsdef.asp?glngUserChoice=29792, should this be explicitly quoted in the article? Otherwise, it might be best to rephrase the lead. zadignose (talk) 14:20, 28 April 2008 (UTC)[reply]

Two months later, I've explicitly made this a quote, and gone to the source it was lifted from. Rewrite it, preferably in less abstruse language, if you want to remove the explicit citation. zadignose (talk) 15:05, 18 June 2008 (UTC)[reply]

P.S. Also note that this text could likely be deleted if it can not be paraphrased, or a Free-Documentation-License can not be provided. zadignose (talk) 15:07, 18 June 2008 (UTC)[reply]

Reword

This article uses 'involvement' without being specific. Examples should be given and the article reworded. — Preceding unsigned comment added by 78.149.44.134 (talk) 17:25, 20 August 2011 (UTC)[reply]

Guideline

doi:10.1182/blood-2014-03-561381 JFW | T@lk 10:37, 27 July 2014 (UTC)[reply]

Updating a sentence

This line "Approximately 500 cases have been reported in the literature to date.[17]" can be edited to include a new source article, Erdheim-Chester Disease: a Concise Review, from 2019 that claims there are 1500 reported cases worldwide. 192.44.242.208 (talk) 13:42, 2 March 2022 (UTC)[reply]

Prognosis

There is a call for a Reference in this section. I don't know enough about Wikipedia to add this, but a believe a relevant reference is:

Journal of Clinical Oncology > List of Issues > Volume 38, Issue 15_suppl > 

Meeting Abstract | 2020 ASCO Annual Meeting I

HEMATOLOGIC MALIGNANCIES—LEUKEMIA, MYELODYSPLASTIC SYNDROMES, AND ALLOTRANSPLANT Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2020.38.15_suppl.7560 Journal of Clinical Oncology - published online before print May 25, 2020

Long-term outcome of 117 patients with Erdheim-Chester disease and mixed histiocytosis receiving targeted therapies (BRAF and MEK inhibitors): A monocentric experience. — Preceding unsigned comment added by 80.193.244.222 (talk) 15:14, 24 March 2022 (UTC)[reply]